InspireMD (NSPR) has shared an update.
InspireMD, Inc. has shared encouraging one-year follow-up results from the C-GUARDIANS trial of their CGuard Carotid Stent System, presented at LINC 2024. The trial, involving 316 patients across the US and EU, demonstrated a low rate of major adverse events, with a primary endpoint event rate of just 1.95%. This data suggests the CGuard system is a promising option for patients with carotid artery stenosis who are at high risk for surgery.
For an in-depth examination of NSPR stock, go to TipRanks’ Stock Analysis page.
